Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 ...

BofA lowered the firm’s price target on Apellis (APLS) to $47 from $61 and keeps a Buy rating on the shares after the company reported Q3 Syfovre revenues that came in below expectations.

The FDA announced marketing authorization of a form of light therapy as the first-ever treatment for dry age-related macular ...

In connection with the Empaveli/Syfovre Transaction completed in 2022, the Trust acquired other current assets. The related amortization expense is recorded in other operating expenses.

If approved, it could become a rival to Apellis Pharma’s Syfovre (pegcetacoplan), which was the first drug cleared to treat geographic atrophy in the US in February. Both drugs are complement ...

After compiling and comparing all our in-house test data and analyzing thousands of customer reviews, we've crowned The DreamCloud Hybrid as this year's best mattress in a box. It offers great ...

However, at Urban List we know the source for the best wardrobe staples can actually be found right under our noses in the form of local Australian labels. With an almost endless pool of independent ...

Add a description, image, and links to the react-native-image-slider-box topic page so that developers can more easily learn about it.

Annotate better with CVAT, the industry-leading data engine for machine learning. Used and trusted by teams at any scale, for data of any scale.